Deloitte Life Sciences HCP Aggregate Spend
Recent laws and public demands for more transparency have caused additional challenges, even for companies who have already implemented HCP Aggregate Spend Solutions.
Talk to us to learn how we can help you comply and capitalize on the hidden data to drive commercial business decisions.
- For every action, there is a reaction: Closing the loop in life sciences analytics
- Signal strength
- Continuous monitoring and continuous auditing
- Clearing the confusion: The what and why of Deloitte Analytics
- Irrational expectations
- Release higher performance through business Analytics
HCP Aggregate Spend
- Full disclosure ahead: A roundtable discussion on HCP transparency
- FCPA compliance: How much is enough?
- Full disclosure ahead: Readying your organization for aggregate spend and beyond
- The implications of health care reform: An overview of key provisions and smart first steps
- Regulatory services for life sciences organizations
- The risk intelligent life sciences company
- Showdown over drug pricing
- Promotional quality assurance eases compliance
- Promoting off-label: Playing by the rules in a regulated industry
New Commercial Model
- S.M.A.R.T. marketing : Transforming the biopharma promotional model by going beyond CLM
- Pharma’s new U.S. commercial model: Promoting the science not the swag
- What payers want: Viewing payers as customers
- Gaining control over HCP spend: A medical device manufacturer meets compliance obligations with a custom application